menu
    • menu
    [{"orgOrder":0,"company":"Faeth Therapeutics","sponsor":"Khosla Ventures","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Financing","leadProduct":"Serabelisb","moa":"||PI3K","graph1":"Oncology","graph2":"Phase I","graph3":"Faeth Therapeutics","amount2":0.02,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0.02,"dosageForm":"Tablet","sponsorNew":"Faeth Therapeutics \/ Khosla Ventures","highestDevelopmentStatusID":"6","companyTruncated":"Faeth Therapeutics \/ Khosla Ventures"},{"orgOrder":0,"company":"Faeth Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Serabelisib","moa":"PI3-kinase p110-alpha subunit","graph1":"Oncology","graph2":"Phase I","graph3":"Faeth Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Faeth Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Faeth Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Faeth Therapeutics","sponsor":"GOG Foundation","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"Paclitaxel","moa":"||PI3-kinase p110-alpha subunit","graph1":"Oncology","graph2":"Phase II","graph3":"Faeth Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Faeth Therapeutics \/ GOG Foundation","highestDevelopmentStatusID":"8","companyTruncated":"Faeth Therapeutics \/ GOG Foundation"},{"orgOrder":0,"company":"Faeth Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Sapanisertib","moa":"Serine\/threonine-protein kinase mTOR","graph1":"Oncology","graph2":"Phase II","graph3":"Faeth Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Faeth Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Faeth Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Faeth Therapeutics","sponsor":"GOG Foundation","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Sapanisertib","moa":"Serine\/threonine-protein kinase mTOR","graph1":"Oncology","graph2":"Phase II","graph3":"Faeth Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Faeth Therapeutics \/ GOG Foundation","highestDevelopmentStatusID":"8","companyTruncated":"Faeth Therapeutics \/ GOG Foundation"},{"orgOrder":0,"company":"Faeth Therapeutics","sponsor":"S2G Ventures | Khosla Ventures | Future Ventures | Digitalis Ventures | KdT Ventures | Cantos | B Capital Group | Avicella | THO Seed Fund","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Financing","leadProduct":"Sapanisertib","moa":"mTORC1\/2","graph1":"Oncology","graph2":"Phase II","graph3":"Faeth Therapeutics","amount2":0.089999999999999997,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0.089999999999999997,"dosageForm":"Undisclosed","sponsorNew":"Faeth Therapeutics \/ S2G Ventures | Khosla Ventures | Future Ventures | Digitalis Ventures | KdT Ventures | Cantos | B Capital Group | Avicella | THO Seed Fund","highestDevelopmentStatusID":"8","companyTruncated":"Faeth Therapeutics \/ S2G Ventures | Khosla Ventures | Future Ventures | Digitalis Ventures | KdT Ventures | Cantos | B Capital Group | Avicella | THO Seed Fund"},{"orgOrder":0,"company":"Faeth Therapeutics","sponsor":"S2G Investments | Khosla Ventures | Future Ventures | Digitalis Ventures | KdT Ventures | Cantos | B Group Capital | Avicella | THO Seed Fund","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Financing","leadProduct":"Sapanisertib","moa":"mTORC1\/mTORC2","graph1":"Oncology","graph2":"Phase II","graph3":"Faeth Therapeutics","amount2":0.089999999999999997,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0.089999999999999997,"dosageForm":"Undisclosed","sponsorNew":"Faeth Therapeutics \/ S2G Investments | Khosla Ventures | Future Ventures | Digitalis Ventures | KdT Ventures | Cantos | B Group Capital | Avicella | THO Seed Fund","highestDevelopmentStatusID":"8","companyTruncated":"Faeth Therapeutics \/ S2G Investments | Khosla Ventures | Future Ventures | Digitalis Ventures | KdT Ventures | Cantos | B Group Capital | Avicella | THO Seed Fund"}]

    Find Clinical Drug Pipeline Developments & Deals by Faeth Therapeutics

    Menu

    Faeth Therapeutics

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Faeth Therapeutics

                            U.S.A arrow
                            AAPS
                            Not Confirmed

                            Faeth Therapeutics

                            U.S.A arrow
                            AAPS
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Sapanisertib

                            Therapeutic Area : Oncology

                            Study Phase : Phase II

                            Sponsor : S2G Investments | Khosla Ventures | Future Ventures | Digitalis Ventures | KdT Ventures | Cantos | B Group Capital | Avicella | THO Seed Fund

                            Deal Size : $92.0 million

                            Deal Type : Financing

                            DEALS_DEV arrow-down

                            Faeth Therapeutics' $92M Funds PIKTOR Phase 2 with 80% Response in Endometrial Cancer

                            Details : The financing for Sapanisertib will support the development of treatments targeting Serine/threonine-protein kinase mTOR in endometrial cancer.

                            Product Name : FTH-003

                            Product Type : Miscellaneous

                            Upfront Cash : Undisclosed

                            October 27, 2025

                            Lead Product(s) : Sapanisertib

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase II

                            Sponsor : S2G Investments | Khosla Ventures | Future Ventures | Digitalis Ventures | KdT Ventures | Cantos | B Group Capital | Avicella | THO Seed Fund

                            Deal Size : $92.0 million

                            Deal Type : Financing

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Faeth Therapeutics

                            U.S.A arrow
                            AAPS
                            Not Confirmed

                            Faeth Therapeutics

                            U.S.A arrow
                            AAPS
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Sapanisertib

                            Therapeutic Area : Oncology

                            Study Phase : Phase II

                            Sponsor : S2G Ventures | Khosla Ventures | Future Ventures | Digitalis Ventures | KdT Ventures | Cantos | B Capital Group | Avicella | THO Seed Fund

                            Deal Size : $92.0 million

                            Deal Type : Financing

                            DEALS_DEV arrow-down

                            Faeth Secures $92M for PIKTOR Phase 2 in Endometrial Cancer

                            Details : The financing for Sapanisertib will support the development of treatments for endometrial cancer targeting Serine/threonine-protein kinase mTOR.

                            Product Name : FTH-003

                            Product Type : Miscellaneous

                            Upfront Cash : Undisclosed

                            October 20, 2025

                            Lead Product(s) : Sapanisertib

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase II

                            Sponsor : S2G Ventures | Khosla Ventures | Future Ventures | Digitalis Ventures | KdT Ventures | Cantos | B Capital Group | Avicella | THO Seed Fund

                            Deal Size : $92.0 million

                            Deal Type : Financing

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Faeth Therapeutics

                            U.S.A arrow
                            AAPS
                            Not Confirmed

                            Faeth Therapeutics

                            U.S.A arrow
                            AAPS
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Serabelisib,Paclitaxel,Sapanisertib

                            Therapeutic Area : Oncology

                            Study Phase : Phase II

                            Sponsor : GOG Foundation

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Faeth, GOG Launch Phase 2 Sapanisertib-Serabelisib Trial for Endometrial Cancer

                            Details : FTH-001 (serabelisib) and FTH-003 (sapanisertib) with paclitaxel, is a novel approach of dual PI3Kɑ-mTORC1/2 inhibition targeting cancer metabolism bein studied in patients with endometrial cancer.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            March 12, 2025

                            Lead Product(s) : Serabelisib,Paclitaxel,Sapanisertib

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase II

                            Sponsor : GOG Foundation

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Faeth Therapeutics

                            U.S.A arrow
                            AAPS
                            Not Confirmed

                            Faeth Therapeutics

                            U.S.A arrow
                            AAPS
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Sapanisertib

                            Therapeutic Area : Oncology

                            Study Phase : Phase II

                            Sponsor : GOG Foundation

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Sapanisertib and Serabelisib (PIKTOR) With Paclitaxel and a Substudy With an Insulin-Suppressing Diet in Patie...

                            Details : Sapanisertib is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Endometrial Neoplasms.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            June 17, 2024

                            Lead Product(s) : Sapanisertib

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase II

                            Sponsor : GOG Foundation

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Faeth Therapeutics

                            U.S.A arrow
                            AAPS
                            Not Confirmed

                            Faeth Therapeutics

                            U.S.A arrow
                            AAPS
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Serabelisib

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Combination of Serabelisib and Insulin Suppressing Diet with or Without Nab-paclitaxel in Subjects with Advanc...

                            Details : Serabelisib is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Neoplasms.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            March 29, 2022

                            Lead Product(s) : Serabelisib

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Faeth Therapeutics

                            U.S.A arrow
                            AAPS
                            Not Confirmed

                            Faeth Therapeutics

                            U.S.A arrow
                            AAPS
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Sapanisertib

                            Therapeutic Area : Oncology

                            Study Phase : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            A Study of Sapanisertib in Relapsed/Refractory NFE2L2-Mutated and Wild-Type Squamous Non-Small Cell Lung Cance...

                            Details : Sapanisertib is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Carcinoma, Non-Small-Cell Lung.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            March 11, 2022

                            Lead Product(s) : Sapanisertib

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            Faeth Therapeutics

                            U.S.A arrow
                            AAPS
                            Not Confirmed

                            Faeth Therapeutics

                            U.S.A arrow
                            AAPS
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Serabelisb,Undisclosed

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Sponsor : Khosla Ventures

                            Deal Size : $20.0 million

                            Deal Type : Financing

                            DEALS_DEV arrow-down

                            Faeth Therapeutics Raises $20M to Advance Precision Nutrition Platform as A New Modality in Cancer Treatment

                            Details : The financing will be used to advance Faeth’s precision nutrition platform as well as its lead candidate FTH01, an isoform-selective PI3Kα inhibitor, Serabelisb, into Phase Ib/II clinical trials this year.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Undisclosed

                            January 18, 2022

                            Lead Product(s) : Serabelisb,Undisclosed

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Sponsor : Khosla Ventures

                            Deal Size : $20.0 million

                            Deal Type : Financing

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth